|
May 21
|
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
|
|
May 21
|
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
|
|
May 21
|
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
|
May 20
|
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
|
|
May 17
|
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
|
|
May 17
|
Dow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today.
|
|
May 16
|
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
|
|
May 16
|
Roche’s New Weight-Loss Data Shows Lilly Isn’t Unbeatable in Obesity
|
|
May 16
|
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
|
|
May 16
|
Stocks to Watch Thursday: Chubb, Deere, Baidu, Walmart, Under Armour
|
|
May 16
|
Roche keeps pace in obesity drug field with early study data
|
|
May 16
|
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial
|
|
May 16
|
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
|
|
May 16
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
|
|
May 15
|
Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
|
|
Feb 21
|
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
|
|
Feb 21
|
Q4 2023 Halozyme Therapeutics Inc Earnings Call
|
|
Feb 19
|
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
|
|
Feb 19
|
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
|
|
Feb 18
|
Roche Holding's (VTX:ROG) Dividend Will Be Increased To CHF9.60
|